PUT/NOVO-NORDISK B/600/0.1/20.09.24 | Market Closed - BOERSE MUENCHEN 19:26:27 28/06/2024 BST | ||
| 0.016 EUR | -5.88% |
|
| Current month | -48.39% | ||
| 1 month | -52.94% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 0.016 | -5.88% |
| 27/06/24 | 0.017 | +13.33% |
| 26/06/24 | 0.015 | -11.76% |
| 25/06/24 | 0.017 | +6.25% |
| 24/06/24 | 0.016 | -51.52% |
Real-time BOERSE MUENCHEN
Last update June 28, 2024 at 07:26 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | Goldman Sachs |
| WKN | GQ4XWD |
| ISIN | DE000GQ4XWD5 |
| Date issued | 14/09/2023 |
| Strike | 600 kr |
| Maturity | 20/09/2024 (83 Days) |
| Parity | 10 : 1 |
| Emission price | 0.51 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.79 € |
|---|---|
| Lowest since issue | 0.015 € |
| Spread | 0.1 € |
| Spread % | 83.33% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.56%
- Stock Market
- Warrants
- Warrant
